Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Such a delight and honor to deliver not one but two Keynote lectures and join dynamic panel discussions at the OncoNext Meeting in São Paulo, Brazil, May 2026.
The conversations around AI, precision oncology, and clinical trials were electric. Brazil is rapidly emerging as a powerhouse for late‑phase registrational studies.
Deep gratitude to Dr. Fábio Franke President‑Elect of the Brazilian Society of Clinical Oncology and a leading force in oncology clinical trials, for the warm hosting and discussions.
A special thank‑you to Dr. Roberto Carmagnani Pestana, Juliana Rodrigues Beal and all the incredible oncologists across Brazil for the thoughtful Q and A, the hospitality, and the truly energizing exchange of ideas.
And sincere appreciation and thanks to Camilla De Gaspari, Manmohan Singh and everyone in the
Pfizer team for the engagement, warm welcome and dedication to innovation for patients.
Yes! Brazil’s oncology community is vibrant, and collaborative.
To advance precision medicine we need to think globally and act locally”
Other articles featuring Vivek Subbiah on OncoDaily.
